

13. <https://www.shionogi.com/global/en/news/2023/02/20230222.html>.
14. Dexamethasone in Hospitalized Patients with Covid-19. The RECOVERY Collaborative Group N Engl J Med 2021; 384 (8) : 693-704.
15. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21 (1) : 337.
16. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health: <https://www.covid19treatmentguidelines.nih.gov/>.
17. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The REMAP-CAP Investigators N Engl J Med 2021; 384 (16) : 1491-502.
18. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Resp Med 2021; 9 (12) : 1407-18.
19. Kojima Y, Nakakubo S, Takei N, et al. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. Medicina 2022; 58 (4) : 513.
20. Lakatos B, Szabó BG, Bobek I, et al. Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. Int J Infect Dis 2022; 125: 233-40.
21. Barnieh L, Gottlieb RL, Malin JJ, et al. Real-world effectiveness of remdesivir for hospitalized patients with COVID-19: systematic review and meta-analysis. Eur Resp J 2022; 60 (suppl 66) : 4498.
22. Garibaldi BT, Wang K, Robinson ML, et al. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) : A Retrospective, Multicenter Comparative Effectiveness Study. Clin Infect Dis 2022; 75 (1) : e516-e24.



日本医師会作成『心肺蘇生法CAB+Dカード』について

◇救急医療部◇

日本医師会が救急蘇生法の普及啓発のため作成・配布しております『心肺蘇生法CAB+Dカード』(二つ折り名刺サイズ)につきて、地域住民(患者等)への配布や、各種研修会でご活用いただきたくご案内申し上げます。

ご希望の方は下記宛に必要部数をご連絡ください。(送料無料)

連絡先：北海道医師会事業第二課

TEL 011-231-1725

FAX 011-210-4514

E-mail 2ka@m.douji.jp

